Amendments to the Claims

Please amend claims 8, 11, 12, 24-27, 29, and 31, as indicated in the Listing of Claims.

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-7 (Canceled)

8. (Currently Amended): A method of ameliorating an autoimmune disease or graft rejection in an animal, the method comprising administering to the animal a therapeutically effective amount of ~~an~~ a monoclonal antibody, capable of suppressing intercellular leukocyte-leukocyte adhesion, wherein the antibody binds to an epitope on the leukocyte adhesion receptor β-chain, thereby ameliorating the autoimmune disease or graft rejection in the animal.

9. (Original): The method of claim 8, wherein the receptor is selected from the group consisting of LFA-1, Mac-1, and Leu M5.

10. (Canceled)

11. (Currently Amended): The method of claim 8, wherein the monoclonal antibody has the specificity of the monoclonal antibody produced by ATCC HB [[X]] 10160.

12. (Currently Amended): The method of claim 8, wherein the antibody is produced by hybridoma cell line ATCC HB [[X]] 10160.

13. (Original): The method of claim 8, wherein the administration is parenteral.

14. (Original): The method of claim 13, wherein the parenteral administration is by subcutaneous, intramuscular, intraperitoneal, intracavity, transdermal, or intravenous injection.

15. (Original): The method of claim 8, wherein said administration is at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

16. (Original): The method of claim 8, wherein the monoclonal antibody is therapeutically labeled.

17. (Original): The method of claim 16, wherein the therapeutic label is selected from the group consisting of a radioisotope, a drug, a lectin, and a toxin.

Claims 18-23 (Canceled)

24. (Currently Amended): A method of ~~ameliorating acquired immunodeficiency syndrome (AIDS), an antoimmune disease, or graft rejection in an animal,~~ suppressing HIV-induced cell fusion, comprising:
~~administering to the animal a therapeutically~~ contacting a leukocyte infected with HIV with an effective amount of an antibody, capable of suppressing intercellular leukocyte-leukocyte adhesion, wherein the antibody binds to an epitope on the leukocyte adhesion receptor β-chain, thereby ~~ameliorating acquired immunodeficiency syndrome (AIDS), an autoimmune disease, or graft rejection in the animal~~ suppressing HIV-induced cell fusion.

25. (Currently Amended): The method of claim 24, wherein the receptor is ~~selected from the group consisting of~~ LFA-1~~, Mac-1, and Leu M5~~.

26. (Currently Amended): The method of claim 24, wherein the monoclonal antibody has the specificity of the monoclonal antibody produced by ATCC HB [[X]] 10160.

27. (Currently Amended): The method of claim 24, wherein the antibody ~~said administration is~~ is administered at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

28. (Previously Presented): The method of claim 24, wherein the monoclonal antibody is therapeutically labeled.

29. (Currently Amended): A method of ameliorating graft rejection in an animal, the method comprising administering to the animal a therapeutically effective amount of an antibody, capable of suppressing intercellular leukocyte-leukocyte adhesion, wherein the antibody binds to an epitope on the leukocyte adhesion receptor β-chain, thereby ameliorating the graft rejection in the patient.

30. (Previously Presented): The method of claim 29, wherein the receptor is selected from the group consisting of LFA-1, Mac-1, and Leu M5.

31. (Currently Amended): The method of claim 29, wherein the antibody has the specificity of the monoclonal antibody produced by ATCC HB [[X]] 10160.

32. (Previously Presented): The method of claim 29, wherein said administration is at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose.

33. (Previously Presented): The method of claim 29, wherein the monoclonal antibody is therapeutically labeled.

34. (Previously Presented): The method of claim 29, wherein the animal is a human.